DBV Technologies Reports Full Year 2025 Financial Results and Business Update

Core Insights - DBV Technologies reported its financial results for the full year 2025, focusing on advancing its clinical development programs and preparing for the commercialization of the VIASKIN® Peanut Patch [2][3] Financial Performance - Operating income for 2025 was $5.6 million, an increase from $4.2 million in 2024, attributed to higher eligible activities for the French Research Tax Credit [11] - Research and Development (R&D) expenses rose by $27.3 million in 2025 compared to 2024, reflecting increased investment in clinical programs [12] - Selling, General and Administrative (SG&A) expenses increased by $4.6 million in 2025, primarily due to market research activities and operational enhancements for the VIASKIN® Peanut Patch launch [12] - The net loss for 2025 was $147.0 million, compared to $113.9 million in 2024, with a net loss per share of $1.05 for 2025 [13] - Cash and cash equivalents stood at $194 million as of December 31, 2025, a significant increase from $32.5 million in 2024, with net cash used for operating activities at $121.2 million [14] Operational Highlights - The company advanced its clinical development programs for the VIASKIN® Peanut Patch in peanut-allergic toddlers and children, reporting positive topline results from the Phase 3 VITESSE trial [8][10] - A supplemental safety study, COMFORT Toddlers, was initiated for peanut-allergic toddlers aged 1 to 3 years [8] - The company appointed new executives to strengthen its leadership team in preparation for the potential commercialization of the VIASKIN® Peanut Patch [9] Anticipated Events - The company plans to submit a Biologics License Application (BLA) for children aged 4 to 7 years in the first half of 2026, with a potential for Priority Review [15] - Completion of enrollment for the COMFORT Toddlers safety study is expected, with topline results anticipated [15] - A BLA submission for 1-3 year olds is anticipated in the second half of 2026 under an Accelerated Approval Pathway [15]